Professor Emeritus of Toxicology Dr. Jaques Decotes, of the Claude Bernard University of Lyon in France, synthesized 500 Ivermectin studies conducted over 40 years. He concluded that Ivermectin as a usage for the treatment of COVID 19 is an effective “therapeutic or prophylactic” (preventative)” and “did not reveal any significant cause for concern”.
“Hundreds of millions of human specimens have been treated with Ivermectin” worldwide over the last three (3) decades. Based on all the data that exists. So, “statements, past or present, that Ivermectin can kill patients, are therefore considered to be misleading as they do not take into account all the medical information that has been accumulated over the last decades” he says.
Ivermectin has been shown in 60 peer reviewed studies that it “shows 74% and 85% improvement for early treatment and prophylaxis of COVID using Ivermectin, and 64% and 96% lower mortality, as well as improvements with ”mortality, hospitalization, recovery, cases, and viral clearance.” He recommends people visit the IVMETTA web-page page called “Ivermectin for COVID-19: real-time meta analysis of 60 studies.” (last updated August 2, 2021) for regularly up-to-date geo-political research trends and analysis. https://ivmmeta.com
Researchers at IVMMETA analyzed the World Health Organization WHO policy regarding Ivermectin. Out of 60 RTC studies, only 13 were included by the WHO to determine their policy outcomes, with no translucency as to why the other 43 studies were omitted. Regarding Ivermectin, the WHO reported a mortality odds ratio of 0.19. Yet, “despite this extremely positive result, they recommended only using Ivermectin in clinical trials.” The WHO analysis contains many flaws. There is “no protocol for data exclusion”, trials included in the origins UNITAID were not included, and “they excluded all epidemiological evidence, although WHO has considered such evidence in the past”. All of this shows WHO medical ethics and evaluation incongruency.
Use of Ivermectin for the pandemic was first “proposed by Kitasato University including the co-discoverer of Ivermectin, Dr. Satoshi Ōmura.” Dr. Kitasato requested the Pharmaceutical company Merck (who sell in Canada) conduct clinical trials of Ivermectin for COVID-19... because Merck has priority to submit an application for an expansion of Ivermectinʼs indications” to treat other Non-COVID conditions. Merck declined.
However, Merck continues to contradict many COVID studies. Merck says use of Ivermectin has "no scientific basis for a potential therapeutic effect against COVID-19 from pre-clinical studies" , “no meaningful evidence for clinical activity or clinical efficacy in patients with COVID-19 disease" and claims there is “a concerning lack of safety data in the majority of studies". IVMETTA concludes that Merck has a conflict of interest because they sell other COVID-19 treatments, that are not Ivermectin- based, and had a $1.2B agreement to supply Molnupiravir to governments.
Japan requested Merck “conduct clinical trials early in the pandemic and Merck declined. Merck may be reluctant to admit this mistake” Merck has only approved Ivermectin for intestinal strongyloidiasis and onchocerciasis, two conditions caused by Parasitic worms. Their brand is called Stromectol® Health Canada approved Stromectol® for this use in 2018, but has not yet approved it, not Ivermectin for COVID.
Health Canada states on their web-site “Ivermectin, an antiparasitic agent, is not recommended for prophylaxis (prevention) or treatment of coronavirus disease.” ”Ivermectin is an oral drug approved in Canada for the treatment of certain parasitic infections (e.g. strongyloidiasis and onchocerciasis)...In vitro data have demonstrated that ivermectin has antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and can prevent viral proteins from binding to and entering cells.” However, Health Canada claims that there is an “absence of evidence showing a clinical benefit.”
More information studies on Ivermectin’s affect on on the molecular mechanisms anthelmintic, antiviral, antimalarial, antimetabolic and anticancer activities are being considered but still have to be conclusively established. Moreover, docking studies identified Ivermectin may interfere with the attachment of the spike protein to the human cell membrane, and is showing anti-viral activity invitro. However, Ivermectin conclusively does not conclusively treat the COVID virus, but Ivermectin does treat the parasites of the Virus, thus the VIRUS symptoms.
Professor Jaques Decotes wrote “At the time of writing, Ivermectin was approved as a prophylactic and/or curative treatment of COVID-19 in a limited number of countries, for instance Belize, Bolivia, Columbia, Moldavia, Zimbabwe…”
“Among 50 929 persons from West Africa treated with Ivermectin, none was reported to have died during the 72-hour post-treatment period [De Sole et al., 1989]. One 38-year-old female patient in poor health condition died at day 10 post-ivermectin but a pre-existing parasitic co-morbidity was considered to be involved. Ivermectin was also given as a single oral dose of 150 μg/kg twice one year apart to 14 000 workers of a rubber plantation in Liberia. Compliance to treatment was 97%. Neither deaths nor severe adverse reactions were reported and 0.5% of treated human subjects developed moderate adverse effects” [Pacqué et al., 1990].
“The present extensive review of adverse events reportedly associated with Ivermectin treatment... With the notable exception of patients with parasitic diseases such as Onchocerciasis or Loa-Loa microfilariae, serious adverse events temporarily associated with Ivermectin were very infrequent. In fact, adverse events were mainly mild to moderate and infrequent. This is confirmed by results reported in patients with scabies or human beings without any ongoing parasitic disease,” says Professor Decotes.
“More recently, no deaths attributable to Ivermectin treatment were recorded in patients with Onchocerciasis during a 3-year randomized controlled trial conducted in Cameroon. In total, 7237 treatments were given, including 2808 doses of placebo; 2226 doses of ivermectin at 150 μg/kg, 475 doses at 400 μg/kg and 1728 doses at 800 μg/kg” Further, “a researcher Kinyanjui revisited results from a Barkwell and Shield's novel framework model of Ivermectin treatments for scabies, a Bayesian approach. They concluded there was no statistical evidence for any excess of deaths.
Ivermectin's safety as a once-daily treatment has been demonstrated and documented. MedinCell tested Ivermectin taken daily in oral form to simulate the continuous release of the active substance by a long-acting injectable. After completion, the study confirms the safety of Ivermectin up to a dose of 100 µg / kg / day in continuous administration over 1 month in healthy volunteers.” There were “no significant difference observed between the treated volunteers and the placebo volunteers in the three cohorts studied successively (daily doses of 50 µg / kg, 75 µg / kg and 100 µg / kg respectively)”
Ivermectin is usually administered in a single dose of 150-200 μg/kg for the treatment of a variety of parasitic diseases. This dose can be administered again once or twice after a few days, or 3 to 6 months after the last oral dose. The Center for Disease Control “recommend an oral dose of 150 μg/kg on days 1, 2, 8, 9, 15, 22 and 29 in patients with crusted scabies.” In most cases, the tested dose ranged between 0.2 mg/kg for 1 day and 0.6 mg/kg for 5 days. “The safety of repeated daily oral administrations on humans of up to 100 μg/kg Ivermectin over 28 days is being evaluated. “At near completion of this study, no safety concern emerged” with MedinCell.
Usually Ivermectin is administered orally, topically or subcutaneously as an injection. Long-acting Ivermectin formulas could provide “protection against Covid-19 and its variants and mutants for several months after a single injection.” It could also be administered to people ``identified as Covid-19 contact cases to protect them” and as a prophylactic (prevention) strategy, given all the safety data. Christopher Douat, CEO of MedinCell says their mdc-TTG program goal is to have an Ivermectin injection product ready for COVID and COVID variants by 2020.
Professor Jaques Decotes concludes that based on all the data presented, "it is fair to say that Ivermectin did not directly induce an excess of deaths in treated groups of human subjects.”
“Statements, past or present, that Ivermectin can kill patients, are therefore considered to be misleading as they do not take into account all the medical information that has been accumulated over the last decades” he states.
“Undoubtedly, uncertainties remain regarding Ivermectin pharmacological effects and mechanisms of action, but when removed, this is not anticipated to alter the main conclusions of this report in any significant way as they rely on an extensive and consistent body of medical publications. Taking into account all the above... the analysis of the available medical data concludes that the safety profile of Ivermectin has so far been excellent in the majority of treated human patients so that ivermectin human toxicity cannot be claimed to be a serious cause for concern.”